ISRG vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intuitive Surgical, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-16.
Intuitive Surgical, Inc. · Healthcare
$388.97
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
ISRG has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ISRG |
PFE |
| Current Price |
$388.97 |
$25.22 |
| Fair Value Estimate |
$564.01 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$137.8B |
$143.7B |
| Forward P/E |
46.5x
|
19.2x
|
| EV / EBITDA |
31.4x
|
12.3x
|
| Price / Sales |
13.0x
|
2.3x
|
| Price / FCF |
48.6x
|
15.2x
|
| Revenue Growth YoY |
+23.0%
|
+5.4%
|
| Gross Margin |
66.3%
|
69.3%
|
| Operating Margin |
30.5%
|
23.4%
|
| Return on Equity |
17.0%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.06%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Intuitive Surgical, Inc. operates in the healthcare sector, specializing in medical devices with a strong focus on robotic-assisted surgery systems. The company demonstrates high business quality with a durable competitive moat supported by a 17.0% return on equity, robust gross margin of 66.3%, and solid operating margin of 30.5%. Revenue and earnings growth in the most recent quarter were impre…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
ISRG |
PFE |
| Zone Low |
$423.01 |
$19.44 |
| Zone High |
$479.41 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|